Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Medical AI-assisted Ultrasound System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medical AI-assisted Ultrasound System market, including market size, share, demand, industry development status, and forecasts for the next few years.
For radiologists, sonographers, and emergency medicine clinicians, diagnostic ultrasound presents a persistent challenge: image interpretation requires extensive training, yet global shortages of skilled sonographers (estimated deficit of 15,000 FTEs in the US alone by 2026) lead to diagnostic delays and operator-dependent variability. Medical AI-assisted ultrasound systems directly address these pain points by integrating artificial intelligence algorithms (deep learning convolutional neural networks) with ultrasound imaging platforms to automate image acquisition, real-time interpretation, and clinical decision support. These systems reduce operator dependency, accelerate exam times, and improve diagnostic accuracy for non-expert users in point-of-care settings. The global market for Medical AI-assisted Ultrasound System was estimated to be worth US3,487millionin2025andisprojectedtoreachUS3,487millionin2025andisprojectedtoreachUS 6,163 million, growing at a CAGR of 8.6% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6092750/medical-ai-assisted-ultrasound-system
Understanding AI-Assisted Ultrasound: Technology and Clinical Value
A Medical AI-assisted Ultrasound System is a medical device that integrates artificial intelligence algorithms (typically deep learning models—CNNs, U-Net architectures for segmentation, transformers for sequence analysis) with ultrasound imaging to enhance the accuracy and efficiency of disease screening, diagnosis, and image interpretation. Core AI functionalities include:
- Automated view recognition: AI identifies anatomical planes (e.g., four-chamber cardiac view, fetal biometry plane, liver sagittal view). The system guides probe positioning with on-screen overlays (green/red feedback). This reduces inter-operator variability by 40-60% (studies, 2025).
- Intelligent measurement: AI automatically measures anatomical structures (fetal head circumference, femur length, nuchal translucency; bladder volume; left ventricular ejection fraction) with sub-millimeter precision, eliminating manual caliper placement, reducing exam time by 40–70%.
- Computer-aided diagnosis (CAD): AI detects and characterizes pathology (e.g., thyroid nodules (TI-RADS score), breast masses (BI-RADS categorization), liver steatosis grading, pneumothorax in lung ultrasound). Sensitivity and specificity approaching or exceeding expert level for specific use cases.
- Workflow automation: Auto-populates structured reports, saves cine loops, triggers measurements, and transfers data to PACS/EHR, reducing documentation time per exam by 2–5 minutes.
The AI models are trained on large, annotated ultrasound databases (100,000–2 million images per model). Regulatory pathways include FDA 510(k) clearance (device software function) or De Novo classification (novel AI-based diagnostic assist). The market includes integrated systems (AI embedded in ultrasound hardware, e.g., GE HealthCare’s SonoLyst AI, Siemens Healthineers’ AI in Acuson Sequoia) and software-only AI (compatible with existing ultrasound machines via DICOM or USB, e.g., Koelis’s prostate AI).
Market Segmentation by Product Type: Desktop, Cart-based, and Portable Systems
The Medical AI-assisted Ultrasound System market is segmented by form factor, which impacts deployment setting and AI integration complexity:
- Desktop AI Ultrasound Systems (Volume-Dominant, ~45% of 2025 revenue): Compact units for OB/GYN clinics, cardiology offices, primary care. Typical AI features: fetal biometry automation, cardiac EF (ejection fraction) auto-calculation, thyroid/liver lesion detection. ASP US$ 20,000–50,000. Market leader: Samsung Medison’s V8/V10 (AI analytics, Fetal INSIGHT), Mindray Resona series.
- Cart-based AI Ultrasound Systems (Highest Revenue, ~55% of market but growing slower, 7.2% CAGR): Full-featured, multi-specialty hospital systems with deep AI integration for cardiology (strain imaging, automated EF, valve planimetry), radiology (liver steatosis quantification, breast lesion segmentation, musculoskeletal nerve tracking), and point-of-care (lung AI for B-lines and pleural effusion). Premium ASP US$ 70,000–180,000. GE Voluson Expert (OB/GYN AI), Canon Aplio i-series, Philips EPIQ Elite—all incorporate AI. Market dynamic: cart-based growth dampened by shift toward portable/handheld devices (lower cost, faster AI adoption in outpatient settings). Legacy cart systems (pre-AI) are not readily upgradeable—customers buying new AI-integrated carts or moving to portable.
- Others (Portable/Handheld AI Ultrasound, Fastest-Growing Segment, projected 15.2% CAGR 2026-2032): Smartphone-connected (Butterfly iQ+, Clarius, EchoNous, Healcerion), tablet-based (Mobisante), or laptop-sized (Konica Minolta SONIMAGE HS1). AI integrated into mobile app: real-time guidance (Tell-You-My-View), automated measurements, and local storage + cloud AI processing (Edge AI). Prices US$ 2,000–8,000, democratizing ultrasound for primary care, remote clinics, and community paramedicine. Butterfly Network’s iQ+ (single-probe, whole-body) with AI auto-B-line counting for lung and auto-bladder volume saw 38% sales growth 2025.
Application Landscape: OB/GYN, Cardiology, Emergency Care, MSK
- Obstetrics and Gynecology Diagnosis (Largest Segment, ~32% of 2025 revenue): AI automates fetal biometry (head circumference HC, biparietal diameter BPD, abdominal circumference AC, femur length FL), estimated fetal weight (EFW), anatomical survey, and first-trimester nuchal translucency measurement. FDA-cleared AI (Samsung’s Fetal INSIGHT, GE SonoLyst) reduces OB exam time from 25–45 minutes to 12–20 minutes, enabling more patients per session (tackling sonographer shortage). A 2025 multi-site study (12 US hospitals, 1200 AI-assisted scans) found 94% of fetal measurements within accepted clinical range (vs 88% manual, 7% improvement) with 41% less time. Emerging AI: detection of fetal congenital anomalies (cleft lip, ventricular septal defects, neural tube defects), real-time sagittal/coronal plane recognition—still investigational (not yet FDA cleared), but promising for mid-pregnancy anatomical survey automation.
- Cardiovascular Disease Screening (Second Largest, ~28%): AI for left ventricular ejection fraction (LVEF) auto-calculation (2D and M-mode, automated contouring) with high concordance to expert (r = 0.92–0.96). Also global longitudinal strain (GLS) auto analysis, left atrial volume, wall motion abnormality detection. 2025 study (JASE, Vol 38(6), 521-530): AI-LVEF (Philips EPIQ CVx AI) had mean absolute error 3.2% vs expert cardiac sonographer (3.0%), non-inferior, requiring 2.3 vs 6.1 minutes. Impact: point-of-care ultrasound (POCUS) in cardiology clinics reduces need for dedicated sonographer.
- Emergency and Critical Care (Fastest-Growing, projected 11.5% CAGR): eFAST (Extended Focused Assessment with Sonography in Trauma) containing AI for pneumothorax detection (lung sliding, A-lines, absence of lung pulse), hemopericardium (cardiac tamponade), intra-abdominal free fluid (Morison’s pouch, splenorenal recess). Siemens’ AcuNav AI can detect pneumothorax in 15 seconds vs 60–90 seconds expert manual. Also COVID-19-era adoption of lung ultrasound (B-line quantification, pleural line abnormalities—AI reduces operator dependency. Butterfly iQ+ AI for lung (auto B-line count) used in 250+ US emergency departments.
- Musculoskeletal and Superficial Organ Examination (MSK) (~12–15%): AI for nerve localization (median nerve at wrist, brachial plexus), rotator cuff tear detection, and thyroid/breast lesion classification. Thyroid AI (TI-RADS auto-assessment) achieved 92% sensitivity, 85% specificity in 2025 meta-analysis (20 studies). Breast AI (BI-RADS classification) sensitivity improved for less-experienced readers (from 70% to 88% with AI assist) (RSNA 2025).
Competitive Landscape and Exclusive Market Observation (2025–2026)
Key Players: Major ultrasound OEMs: GE HealthCare (SonoLyst, Voluson AI), Siemens Healthineers (Acuson AI, Syngo AI Workplace), Philips Healthcare (EPIQ AI, Lumify handheld), Canon Medical Systems (Aplio i-series iDMS technology), Samsung Medison (V series AI, Fetal INSIGHT). Chinese OEMs: Mindray (Resona R9 series, “Smart Planes” AI for fetal, thyroid), Sonoscape Medical (S series AI, growing international), United Imaging Healthcare, Shenzhen Landwind Industry. Handheld specialists: Butterfly Network (iQ+ single-probe AI, market leader in handheld AI, >70,000 devices shipped). Clarius Mobile Health (30+ AI models for OB, MSK, lung), Healcerion, EchoNous (Kosmos platform), Mobisante. Japanese OEMs: Hitachi Healthcare (HI VISION AI, liver steatosis quantification), Fujifilm Healthcare, Konica Minolta, Shimadzu, BK Medical (intraoperative ultrasound, urology AI, prostate guidance). Esaote (Italy, musculoskeletal AI), Alpinion Medical Systems, VINNO (China, MSK AI), Bionet (Korea, point-of-care AI), Koelis (France, prostate fusion biopsy AI), MedGyn (OB/GYN AI), SonoScape Europe, Terason, Zonare (now part of Mindray), Analogic Corporation (BK Medical), SuperSonic Imagine (France, shear wave + AI).
Exclusive Industry Insight (H1 2026): The AI-assisted ultrasound market reveals divergent strategies between incumbent OEMs and software-first AI vendors:
- OEM integrated strategy (GE, Siemens, Philips, Canon, Samsung, Mindray): Embed AI natively in hardware—dedicated GPU/AI chips (NVIDIA Jetson or Intel Movidius VPU) within ultrasound console, real-time processing at 30–60 fps, no internet required. OEMs control entire stack, optimized for closed-system AI. Differentiates premium devices (e.g., GE Voluson Expert with SonoLyst commands 15–20% price premium vs non-AI Voluson). Competitive advantage: scale (global distribution, service network, customer relationships). Downside: legacy installed base cannot upgrade to AI without buying new hardware—creates replacement cycle opportunity but also customer friction (some hospitals stick with legacy vs replace).
- Software-first or AI plugin vendors (e.g., Koelis, some AI from EchoNous, Butterfly’s app-based AI): AI runs on connected host (smartphone, tablet, laptop) via USB or wireless connection to any ultrasound probe that supports DICOM or raw RF data output. Some OEMs restrict AI plugin access (proprietary API not open). Software AI vendors target POCUS users (handheld adopters) and smaller clinics that cannot afford premium OEM AI systems. Scalable distribution via app stores. Lower price point (Butterfly AI included in probe cost, Koelis software $5,000–10,000 one-time). But software-only AI faces integration challenges (latency, data security (patient data to cloud), interoperability with PACS/EHR).
- Emerging hybrid model (Philips Lumify with Reacts? Not exactly): Some OEMs allow AI plugins from third-party validated vendors (FDA-clearance required). Not yet widespread due to liability concerns if third-party AI fails. Trend likely towards OEM-controlled AI ecosystems.
Key regulatory milestone: FDA’s final guidance “Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan” (updated Dec 2025) introduces Predetermined Change Control Plans (PCCP) allowing AI to learn/adapt post-market without requiring new 510(k). This benefits ultrasound AI (models can improve from real-world data while maintaining safety). First PCCP-authorized ultrasound AI expected Q2 2026 (likely from Philips or GE).
Future Outlook (2026–2032): Drivers, Reimbursement, and Challenges
Growth Drivers:
- Healthcare workforce shortages: Global radiologist/sonographer gap accelerating AI adoption (automate routine measurements, reduce exam time, enable non-specialists to perform basic scans). US, UK, Germany, China all impacted. WHO estimates 10 million additional health workers needed by 2030, AI-assisted ultrasound mitigates by task-shifting to nurses/midwives (OB).
- POCUS adoption expansion: Point-of-care ultrasound (POCUS) increasingly used in general practice, home care, sports medicine, low-resource settings (global health). Handheld AI ultrasound democratizing imaging to rural clinics (India, Africa). Bill & Melinda Gates Foundation’s AI Ultrasound for Maternal Health program (2024-2027, $25 million) deploying Butterfly iQ+ AI in sub-Saharan Africa for fetal gestational age dating and malpresentation detection. Each device serves ~5000 patients/year.
- Reimbursement for AI-assisted interpretation: CMS (USA) created Category III CPT code 0800T for AI-assisted ultrasound interpretation (2026 proposed rule, final expected 2026 H2), reimbursing $18–28 per study for computer-aided detection/diagnosis (CAD) feature (plus standard ultrasound payment). Private payers expected to follow (2–3 year lag). This unlocks economic incentive for AI purchase beyond workflow efficiency.
- AI improving non-expert performance: Randomized controlled trial (Radiology 2025, 305(1): 212-220) tested non-expert physicians (internists, no prior ultrasound) performing AI-assisted cardiac US (LVEF assessment) vs standard manual. AI-assisted group achieved accuracy 88% of expert (vs 62% manual), enabling primary care screening for heart failure. Meta-analysis 18 studies across OB, cardiac, thyroid, lung shows AI raises non-expert sensitivity by 12-25% and specificity by 8-15% across use cases. This encourages health systems to deploy AI ultrasound in community hospitals lacking specialist sonographers.
Constraints:
- Data heterogeneity and bias: Most AI models trained on data from high-resource settings (North America, Europe, China academic hospitals). Performance drop when applied to diverse populations (different skin tones, body habitus, disease prevalence). 2025 study (Lancet Digital Health) found lung ultrasound AI less accurate for COVID pneumonia in darker skin tones (sensitivity 78% vs 91% lighter skin) due to training data imbalance. Solution requires inclusive datasets, but data acquisition costly.
- Integration with existing workflows: AI results must integrate into PACS/EHR without extra clicks/hassle. Legacy ultrasound machines can’t run AI (no GPU). PACS integration non-standard (some hospitals require HL7/FHIR interfaces not implemented). Adds friction, reduces adoption.
- Physician liability/oversight: Medico-legal: if AI suggests diagnosis that clinician overrules, and outcome is poor, who is liable? Current guidance (FDA, AMA, ACR) positions AI as decision-support (not autonomous), final interpretation by clinician. But courts yet to adjudicate. This uncertainty slows adoption in risk-averse systems.
- Regulatory complexity for updates: Software AI iterative updates (e.g., improve model for thyroid nodule detection) requires FDA submission (510(k) unless PCCP in place). Many vendors slow-walk improvements to avoid re-submission. PCCP may resolve but early days.
The report projects that North America will remain largest market (38% share), followed by Europe (28%) and Asia-Pacific (fastest-growing, 10.4% CAGR 2026-2032) driven by China’s AI initiatives and government ultrasound screening programs (breast, thyroid). Handheld AI ultrasound will surpass 30% of AI-system unit volume by 2029 (from ~15% in 2025) as prices drop and AI capabilities match cart-based for primary-care appropriate use cases. Integration of large language models (LLMs) into AI ultrasound (e.g., automatically generating structured reports from findings, recommending next imaging steps) is early but trending (research phase).
Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
